Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents

References

• SEER Cancer Statistics Factsheets, Lung and Bronchus, National Cancer Institute, Bethesda, MD, [cited 2017 10 April]. Available from: https://seer.cancer.gov/statfacts/html/lungb.html
   Google Scholar
• Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(Suppl 1):5–13. 10.1634/theoncologist.13-S1-5. PubMed PMID: 18263769; eng.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385–2394. DOI:10.1056/NEJMoa1214886. PubMed PMID: 23724913; eng.
   PubMed Web of Science ®Google Scholar
• Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017 Jun 06. DOI:10.1056/NEJMoa1704795. PubMed PMID: 28586279; eng.
   Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England J Med. 2009;361(10):947–957. DOI:10.1056/NEJMoa0810699. PubMed PMID: 19692680.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629–640. DOI:10.1056/NEJMoa1612674. PubMed PMID: 27959700; eng.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015 Feb 12;372(7):683–684. doi:10.1056/NEJMc1415359. PubMed PMID: 25671264; eng.
   PubMed Web of Science ®Google Scholar
• Zhang P, Ma Y, Lv C, et al. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 2016 Nov;107(11):1563–1571. DOI:10.1111/cas.13072. PubMed PMID: 27581532; PubMed Central PMCID: PMCPMC5132280. eng.
   PubMed Web of Science ®Google Scholar
• Spigel DR, Gettinger SN, Horn L, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). May 2013: Journal of Clinical Oncology 31, no. 15_suppl. p. 8008-8008.
   Google Scholar
• Kerr KM, Tsao M-S, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thor Oncol. 2015;10(7):985–989.
   PubMed Web of Science ®Google Scholar
• Besse B, Johnson M, Janne PA, et al. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). Eur J Cancer. 2015;51:S717–S718.
   Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2014;387(10030):1837–1846.
   Web of Science ®Google Scholar
• Pollack BP. EGFR inhibitors, MHC expression and immune responses: can EGFR inhibitors be used as immune response modifiers? Oncoimmunology. 2012 Jan 01;1(1):71–74. doi:10.4161/onci.1.1.18073. PubMed PMID: 22720215; PubMed Central PMCID: PMCPMC3376950. eng.
   PubMed Web of Science ®Google Scholar
• Pollack BP, Sapkota B, Cartee TV. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes. Clin Cancer Res. 2011 Jul 01;17(13):4400–4413. doi:10.1158/1078-0432.ccr-10-3283. PubMed PMID: 21586626; eng.
   PubMed Web of Science ®Google Scholar
• Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014 Feb;124(2):687–695. DOI:10.1172/jci67313. PubMed PMID: 24382348; PubMed Central PMCID: PMCPMC3904601. eng.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. FDA expands approved use of Opdivo in advanced lung cancer FDA 2015 [cited 2017 25 April]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm466413.htm
   Google Scholar
• Administration USFaD. Pembrolizumab (KEYTRUDA) Checkpoint Inhibitor FDA 2016 [cited 2017 25 April]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526430.htm
   Google Scholar
• Garassino MC, Vansteenkiste JF, Kim J, et al. Durvalumab in ≥3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: results from the phase 2 ATLANTIC study. World Conference on Lung Cancer. 2016.
   Google Scholar
• Garassino MC, Cho BC, Gray JE, et al. Durvalumab in ≥3rd-line EGFR mutant/ALK+, locally advanced or metastatic NSCLC: results from the phase 2 ATLANTIC study. 2017 European Lung Cancer Conference; May 5-8, 2017; Geneva, Switzerland. Abstract 82O.
   Google Scholar
• Kaufman HL, Russell J, Hamid O, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct 01;17(10):1374–1385. DOI:10.1016/S1470-2045(16)30364-3.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017 May;18(5):599–610. 10.1016/S1470-2045(17)30240-1
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC. Treating ALK-positive lung cancer–early successes and future challenges. Nat Rev Clin Oncol. 2012 Apr 03;9(5):268–277. doi:10.1038/nrclinonc.2012.43. PubMed PMID: 22473102; PubMed Central PMCID: PMCPMC4142046. eng.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. DOI:10.1016/S0140-6736(16)32517-X.
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Atezolizumab (TECENTRIQ) FDA 2016 [cited 2017 25 April]. Available from: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm525780.htm
   Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1–10. doi:10.1016/j.immuni.2013.07.012. PubMed PMID: 23890059; eng.
   PubMed Web of Science ®Google Scholar
• Apetoh L, Ladoire S, Coukos G, et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26(9):1813–1823.
   PubMed Web of Science ®Google Scholar
• Peng J, Hamanishi J, Matsumura N, et al. Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-kappaB to foster an immunosuppressive tumor microenvironment in ovarian cancer. Cancer Res. 2015 Dec 01;75(23):5034–5045. DOI:10.1158/0008-5472.can-14-3098. PubMed PMID: 26573793; eng.
   PubMed Web of Science ®Google Scholar
• Grabosch S, Zeng F, Zhang L, et al. PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer. J Immunother Cancer. 2015 Nov 04;3(Suppl 2):P302–P302. DOI:10.1186/2051-1426-3-S2-P302. PubMed PMID: PMC4649395.
   Google Scholar
• Giaccone G, Camidge DR, Liu SV, et al. Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): a phase Ib study. European Cancer Congress. 2015; Abstract 513.
   Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. New England J Med. 2006;355(24):2542–2550. DOI:10.1056/NEJMoa061884. PubMed PMID: 17167137.
   PubMed Web of Science ®Google Scholar
• Institute NC. FDA Approval for Bevacizumab National Cancer Institute[ cited 2017 25 April]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-bevacizumab - Anchor-NSCLC
   Google Scholar
• Patel JD, Socinski MA, Garon EB, et al. PointBreak: a randomized phase iii study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non–small-cell lung cancer. J Clin Oncol. 2013;31(34):4349–4357. DOI:10.1200/jco.2012.47.9626. PubMed PMID: 24145346.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point [Insight]. Nature. 2017 Jan 19;541(7637):321–330. DOI:10.1038/nature21349. http://www.nature.com/nature/journal/v541/n7637/abs/nature21349.html - supplementary-information.
   PubMed Web of Science ®Google Scholar
• Bouzin C, Brouet A, de Vriese J, et al. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J Immunol. 2007;178(3):1505–1511.
   PubMed Web of Science ®Google Scholar
• Borgström P, Hughes GK, Hansell P, et al. Leukocyte adhesion in angiogenic blood vessels. Role of E-selectin, P-selectin, and beta2 integrin in lymphotoxin-mediated leukocyte recruitment in tumor microvessels. J Clin Invest. 1997;99(9):2246–2253. PubMed PMID: PMC508056.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774–4782. DOI:10.1158/0008-5472.can-07-6307. PubMed PMID: 18559524; eng.
   PubMed Web of Science ®Google Scholar
• Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143–155. PubMed PMID: 24411639.
   PubMed Web of Science ®Google Scholar
• Ingelheim B. Vargatef® (nintedanib) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy 2014 [ cited 2017]. Available from: https://www.boehringer-ingelheim.com/press-release/vargatef-nintedanib-approved-eu-nsclc
   Google Scholar
• Institute NC. FDA Approval for Vandetanib National Cancer Institute 2013 [ cited 2017 25 April]. Available from: https://www.cancer.gov/about-cancer/treatment/drugs/fda-vandetanib
   Google Scholar
• de Boer RH. Vandetanib in advanced non small cell lung cancer: a promise unfulfilled. Translational Lung Cancer Res. 2013 Oct 06 /received Nov 08/accepted;2(1):E7–E9. DOI:10.3978/j.issn.2218-6751.2012.11.03. PubMed PMID: PMC4367652.
   PubMedGoogle Scholar
• O’Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011 Aug;12(8):795–805. DOI:10.1016/s1470-2045(11)70189-9. PubMed PMID: 21782507; eng.
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001 Sep;37(Suppl 4):S9–15. PubMed PMID: 11597399; eng.
   PubMed Web of Science ®Google Scholar
• Kawaguchi T, Koh Y, Ando M, et al. Prospective analysis of oncogenic driver mutations and environmental factors: Japan molecular epidemiology for lung cancer study. J Clin Oncol. 2016 Jul 01;34(19):2247–2257. DOI:10.1200/jco.2015.64.2322. PubMed PMID: 27161973; eng.
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380–2388. DOI:10.1056/NEJMoa0909530. PubMed PMID: 20573926; eng.
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239–246. DOI:10.1016/s1470-2045(11)70393-x. PubMed PMID: 22285168; eng.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327–3334. DOI:10.1200/jco.2012.44.2806. PubMed PMID: 23816960; eng.
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol. 2006 Jun;11(3):190–198. DOI:10.1007/s10147-006-0583-4. PubMed PMID: 16850125; eng.
   PubMedGoogle Scholar
• Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 2009 May;10(5):432–433. DOI:10.1016/s1470-2045(09)70110-x. PubMed PMID: 19410185; eng.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20;350(21):2129–2139. DOI:10.1056/NEJMoa040938. PubMed PMID: 15118073; eng.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Maruvka YE, Michor F, et al. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013 Mar 10;31(8):1070–1080. DOI:10.1200/jco.2012.43.3912. PubMed PMID: 23401451; PubMed Central PMCID: PMCPMC3589701. eng.
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013 Dec;3(12):1355–1363. DOI:10.1158/2159-8290.cd-13-0310. PubMed PMID: 24078774; PubMed Central PMCID: PMCPMC3864135. eng.
   PubMed Web of Science ®Google Scholar
• Rangachari D, VanderLaan PA, Shea M, et al. Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma. J Thorac Oncol. 2017;12(5):878–883.
   PubMed Web of Science ®Google Scholar
• Azuma K, Ota K, Kawahara A, et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. Ann Oncol. 2014 Oct;25(10):1935–1940. DOI:10.1093/annonc/mdu242. PubMed PMID: 25009014; eng.
   PubMed Web of Science ®Google Scholar
• Soo RA, Kim HR, Asuncion BR, et al. Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. Lung Cancer. 2017 Mar;105:17–22. DOI:10.1016/j.lungcan.2017.01.008. PubMed PMID: 28236980; eng.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang L, Li Y, et al. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther. 2014;7:567–573.DOI:10.2147/ott.s59959. PubMed PMID: 24748806; PubMed Central PMCID: PMCPMC3990506. eng.
   PubMed Web of Science ®Google Scholar
• Lee CK, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017 Feb;12(2):403–407. DOI:10.1016/j.jtho.2016.10.007. PubMed PMID: 27765535; eng.
   PubMed Web of Science ®Google Scholar
• D’Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015 Jan 06;112(1):95–102. DOI:10.1038/bjc.2014.555. PubMed PMID: 25349974; PubMed Central PMCID: PMCPMC4453606. eng.
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Chow LQ, Kim DW, et al. 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC. J Thorac Oncol. 2016;11(4):S79.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Yang J, Yu H, et al. 136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial. J Thorac Oncol. 2016 Apr;11(4Suppl):S115. PubMed PMID: 27198274; eng.
   PubMedGoogle Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 Aug 02;448(7153):561–566. DOI:10.1038/nature05945. PubMed PMID: 17625570; eng.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693–1703. DOI:10.1056/NEJMoa1006448. PubMed PMID: 20979469; PubMed Central PMCID: PMCPMC3014291. eng.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 01;18(5):1472–1482. DOI:10.1158/1078-0432.ccr-11-2906. PubMed PMID: 22235099; PubMed Central PMCID: PMCPMC3311875. eng.
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Kim T, Crinò L, et al. Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): results from the confirmatory phase 3 ASCEND-5 study. Ann Oncol. 2016;27(suppl6):LBA42_PR.
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, de Petris L, et al. Alectinib in crizotinib-refractory alk-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016 Mar 01;34(7):661–668. DOI:10.1200/jco.2015.63.944310.1200/jco.2016.34.4_suppl.661. PubMed PMID: 26598747; eng.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016 Feb;17(2):234–242. DOI:10.1016/s1470-2045(15)00488-x. PubMed PMID: 26708155; PubMed Central PMCID: PMCPMC4752892. eng.
   PubMed Web of Science ®Google Scholar
• Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol. 2012 Jan;7(1):90–97. DOI:10.1097/JTO.0b013e31823c5c32. PubMed PMID: 22134072; PubMed Central PMCID: PMCPMC3931519. eng.
   PubMed Web of Science ®Google Scholar
• Koh J, Jang JY, Keam B, et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1alpha and STAT3. Oncoimmunology. 2016 Mar;5(3):e1108514. DOI:10.1080/2162402x.2015.1108514. PubMed PMID: 27141364; PubMed Central PMCID: PMCPMC4839370. eng.
   PubMed Web of Science ®Google Scholar
• Ota K, Azuma K, Kawahara A, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015 Sep 01;21(17):4014–4021. DOI:10.1158/1078-0432.ccr-15-0016. PubMed PMID: 26019170; eng.
   PubMed Web of Science ®Google Scholar
• Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999 Jan 21;18(3):813–822. DOI:10.1038/sj.onc.1202367. PubMed PMID: 9989833; eng.
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001 Mar 01;410(6824):37–40. doi:10.1038/35065000. PubMed PMID: 11242034; eng.
   PubMed Web of Science ®Google Scholar
• Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997 Apr;9(2):180–186. PubMed PMID: 9069255; eng.
   PubMed Web of Science ®Google Scholar
• Vella LJ, Pasam A, Dimopoulos N, et al. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells. Cancer Immunol Res. 2014 Apr 2;4:351–360. 10.1158/2326-6066.cir-13-0181. PubMed PMID: 24764582; eng.
   Web of Science ®Google Scholar
• Liu L, Mayes PA, Eastman S, et al. The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4. Clin Cancer Res. 2015 Apr 01;21(7):1639–1651. DOI:10.1158/1078-0432.ccr-14-2339. PubMed PMID: 25589619; eng.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225–1231.
   PubMed Web of Science ®Google Scholar
• Yamamoto R, Nishikori M, Tashima M, et al. B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci. 2009 Nov;100(11):2093–2100. DOI:10.1111/j.1349-7006.2009.01302.x. PubMed PMID: 19703193; eng.
   PubMed Web of Science ®Google Scholar
• Berthon C, Driss V, Liu J, et al. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010 Dec;59(12):1839–1849. DOI:10.1007/s00262-010-0909-y. PubMed PMID: 20814675; PubMed Central PMCID: PMCPMC2945474. eng.
   PubMed Web of Science ®Google Scholar
• Bendell J, Kim T, Goh B, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). J Clin Oncol. 2016;34:2016.
   Web of Science ®Google Scholar
• Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11–28. DOI:10.1146/annurev-med-062913-051343. PubMed PMID: 26473415; eng.
   PubMed Web of Science ®Google Scholar
• Lastwika KJ, Wilson W 3rd, Qk L, et al. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res. 2016 Jan 15;76(2):227–238. DOI:10.1158/0008-5472.can-14-3362. PubMed PMID: 26637667; eng.
   PubMed Web of Science ®Google Scholar
• Zheng H, Zhao W, Yan C, et al. HDAC inhibitors enhance T-cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2016 Aug 15;22(16):4119–4132. DOI:10.1158/1078-0432.ccr-15-2584. PubMed PMID: 26964571; PubMed Central PMCID: PMCPMC4987196. eng.
   PubMed Web of Science ®Google Scholar
• Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017 Feb 06. DOI:10.1158/1078-0432.ccr-16-3215. PubMed PMID: 28167507; eng.
   PubMed Web of Science ®Google Scholar
• Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15;174(12):7516–7523. PubMed PMID: 15944250; eng.
   PubMed Web of Science ®Google Scholar
• Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004 Mar 01;58(3):862–870. DOI:10.1016/j.ijrobp.2003.09.012. PubMed PMID: 14967443; eng.
   PubMed Web of Science ®Google Scholar
• Sharabi AB, Nirschl CJ, Kochel CM, et al. Stereotactic radiation therapy augments antigen-specific pd-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2015 Apr 3;4:345–355. 10.1158/2326-6066.cir-14-0196. PubMed PMID: 25527358; PubMed Central PMCID: PMCPMC4390444. eng.
   Web of Science ®Google Scholar
• Gong X, Li X, Jiang T, et al. Combined radiotherapy and anti-PD-L1 antibody synergistically enhances antitumor effect in non-small cell lung cancer. J Thorac Oncol. 2017 Jul;12(7):1085–1097. DOI:10.1016/j.jtho.2017.04.014. PubMed PMID: 28478231; eng.
   PubMed Web of Science ®Google Scholar
• Levy A, Massard C, Soria J-C, et al. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016 Nov;68:156–162. DOI:10.1016/j.ejca.2016.09.013
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Imfinzi significantly reduces the risk of disease worsening or death in the Phase III PACIFIC trial for Stage III unresectable lung cancer 2017 [ cited 2017 15 June]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2017/imfinzi-significantly-reduces-the-risk-of-disease-worsening-or-death-in-the-phase-iii-pacific-trial-for-stage-iii-unresectable-lung-cancer-12052017.html
   Google Scholar
• Xu J, Escamilla J, Mok S, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013 May 01;73(9):2782–2794. DOI:10.1158/0008-5472.can-12-3981. PubMed PMID: 23418320; PubMed Central PMCID: PMCPMC4097014. eng.
   PubMed Web of Science ®Google Scholar
• Crittenden MR, Cottam B, Savage T, et al. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiation therapy. PLoS One. 2012;7(6):e39295. DOI:10.1371/journal.pone.0039295. PubMed PMID: 22761754; PubMed Central PMCID: PMCPMC3386283. eng.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov;17(11):1497–1508. DOI:10.1016/s1470-2045(16)30498-3. PubMed PMID: 27745820; eng.
   PubMed Web of Science ®Google Scholar
• Karasaki T, Nagayama K, Kuwano H, et al. An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer. J Thorac Oncol. 2017 May;12(5):791–803. DOI:10.1016/j.jtho.2017.01.005. PubMed PMID: 28088513; eng.
   PubMed Web of Science ®Google Scholar